Diabetes Mellitus Clinical Trial
Official title:
Control of Diabetes and Periodontitis Through a New Anti-inflammatory Nordic Diet
There is a significant and growing interest in nutrition and health in the general population
and there is also, paradoxically, an increasing problem with obesity and general debilitating
conditions of affluence, such as type 2 diabetes mellitus. Igelösa Life Science AB has
developed a modified Okinawan-based Nordic Diet (OBND) diet based on evidence primarily from
the diet of the long-lived and healthy Okinawa population. The diet includes fish and whole
grains, with a high level of vegetables, but is low in fat. In 2016, a clinical nutrition
study was carried out at Kristianstad University with the intention to determine if the OBND
resulted in reductions/changes in clinical and medical markers of importance for treatment of
diabetes mellitus and gingivitis/periodontitis. The diet had a positive impact on the
clinical progress of otherwise debilitating conditions such as diabetes and the health
benefits on clinical parameters was extremely rapid, that is, within two weeks. Not only did
the patients with type 2 diabetes receive the OBND, their partners were also offered the same
option. This is a key innovation and the participants stated that it was a great support,
which facilitated adherence and promotes the long-term impact on health. Ingrained habits
such as poor diet, can only be defeated by a concerted team effort and our work to date
provides a glimpse of the potential benefits to Sweden and the rest of the developed world
through this shared approach.
Initial studies have shown promising effects of the OBND on both diabetes and periodontal
conditions. The objective of this study is to compare the OBND to the current recommended
standard diet. Assuming the study provides positive evidence of health impact due to improved
food quality, it will also be seen that the production and delivery of such 'healthy-living'
meals will be of commercial interest for industry. The mission is to offer an evidence-based
natural food alternative that both prevents disease and improves the health status of
individuals with diabetes. The long-term goal is to design efficient and effective products
that will protect against diabetes and other chronic diseases. The combination of scientific
credibility and commercial interests may be a key factor to transfer the new knowledge about
healthy dieting into actual improvements in public health.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | December 2019 |
Est. primary completion date | November 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - minimum 20 teeth - HbA1c = 60-80 mmol/mol (diabetics), HbA1c < 42 mmol/mol (control) - be able to receive food delivery monday, wednesday, friday - Scandinavian background Exclusion Criteria: - use of tobacco products - pregnancy - lactose, celiac- or garlic intolerance - blood pressure = 180 mm Hg - have visited dental clinic within one month Before study start or currently are undergoing dental/dental hygienist treatment - have rheumatoid arthritis - for Medical reasons need treatment with antibiotics or who has been treated with antiobiotics within one month before study |
Country | Name | City | State |
---|---|---|---|
Sweden | University of Kristianstad | Kristianstad | Skåne |
Lead Sponsor | Collaborator |
---|---|
Kristianstad University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HbA1c | Changes in levels of HbA1c (mmol/mol) in serum before and after study procedures | Baseline, 2, 4, and 26 weeks | |
Secondary | Pro-inflammatory cytokines | Change in levels of pro-inflammatory cytokines (pg/ml) in serum and gingival fluid in relation to gingival bleeding, before and after study procedures | Baseline, 2, 4, and 26 weeks | |
Secondary | Gingivitis | Changes in the extent of gingivitis, as determined by the severity of gingival bleeding (%), before and after the study procedures | Baseline, 2, 4, and 26 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |